Services contract with Joslin and Pharma Partner

Renalytix

29/07/2025 07:00

RNS Number : 8895S

Renalytix PLC

29 July 2025

 

Renalytix plc

("Renalytix" or the "Company")

 

Services contract with Joslin Diabetes Center and Major Pharma Partner

 

Renalytix expands pharma services for proteomics research and precision diagnostics development

 

LONDON and NEW YORK, 29 July 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that it has been contracted to undertake a biomarker research and precision diagnostics programme with Joslin Diabetes Center ("JDC") and a leading global pharmaceutical company.  This development work has begun on a completed phase 3 GLP-1 agonist clinical trial targeting management of blood sugar levels in people with Type 2 diabetes.

 

Under the contract, Renalytix will examine the clinical utility of 21 circulating proteins that are most strongly associated with progression to end-stage kidney disease.  This panel of proteins, when measured on the Olink Proximity Extension Assay (PEA) proteomics platform, are collectively referred to as the Joslin Kidney Panel (JKPTM). The data generated will inform strategy for future drug clinical trials. Results are expected to be published in 2026.

 

Renalytix has agreed exclusive access with JDC for the use of the proprietary JKPTM which has been shown to have a wide range of potential applications including prognosis of Cardiovascular and Kidney disease progression, prediction of drug response and monitoring of impact of care.  

 

Renalytix believes this proprietary technology significantly expands the Renaltyix services offering to Pharma for Proteomics Biomarker Research and Development and has substantial services revenue value from supporting current and next generation pharmaceutical drug development and commercial programmes in Cardiovascular, Renal and Metabolic Diseases (CVRM).

 

Fergus Fleming, Chief Technology Officer of Renalytix said: "Today's announcement is a significant milestone in our journey to bring precision diagnostics solutions to patients with chronic disease and is built on years of world class research from the laboratory of our long-time collaborator, Prof. Andrzej Krolewski at the Joslin Diabetes Center. Having developed and implemented kidneyintelX.dkd as the first precision diagnostic test in chronic kidney disease and having seen the golden age of new therapies coming to market in recent years, we now set our sights on the next wave of innovation where we believe the role of novel biomarkers in clinical practice will be pivotal to delivering the best possible outcomes for patients with Diabetes and its complications including Kidney and Cardiovascular disease. This expansion of our multi-modal precision medicine platform will accelerate the rate of data generation with Pharma and Academic partners necessary to fuel product development and clinical adoption of precision medicine in Chronic Disease."

 

For further information, please contact:

 

Renalytix plc
www.renalytix.com
James McCullough, CEO
Via Walbrook PR
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)
Tel:+44 (0)20 3470 0470
Jeff Keating / David Hignell(Corporate Finance)
Vadim Alexandre (Corporate Broking)
Oberon Capital (Joint Broker)
Tel: +44 (0)20 3179 5300
Mike Seabrook / Nick Lovering
Walbrook PR Limited
Tel: 020 7933 8780 orrenalytix@walbrookpr.com
Paul McManus / Alice Woodings
Mob: 07980 541 893 / 07407 804 654


 

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.

 

The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).

 

KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix.

 

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Part of Beth Israel Lahey Health, Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. Joslin develops and disseminates innovative patient therapies and scientific discoveries throughout the world. A part of Beth Israel Lahey Health, Joslin is affiliated with Harvard Medical School and one of only 18 NIH-designated Diabetes Research Centers in the United States.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
CNTUWSRRVBUBUUR